Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity

Abstract

This commentary provides the authors' perspective on the article "Ipilimumab and a poxviral vaccine targeting prostatespecific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial", which has recently been published in The Lancet Oncology. © 2012 Landes Bioscience.